DE69837170T2 - Festphasige native chemische Ligation von ungeschützten oder n-cystein-geschützten Peptiden in wässrigen Lösungen - Google Patents

Festphasige native chemische Ligation von ungeschützten oder n-cystein-geschützten Peptiden in wässrigen Lösungen Download PDF

Info

Publication number
DE69837170T2
DE69837170T2 DE69837170T DE69837170T DE69837170T2 DE 69837170 T2 DE69837170 T2 DE 69837170T2 DE 69837170 T DE69837170 T DE 69837170T DE 69837170 T DE69837170 T DE 69837170T DE 69837170 T2 DE69837170 T2 DE 69837170T2
Authority
DE
Germany
Prior art keywords
peptide
solid phase
terminal
ligation
resin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69837170T
Other languages
German (de)
English (en)
Other versions
DE69837170D1 (de
Inventor
Lynne Canne
Stephen B.H. Kent
Reyna Simon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amylin Pharmaceuticals LLC
Original Assignee
Amylin Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amylin Pharmaceuticals LLC filed Critical Amylin Pharmaceuticals LLC
Application granted granted Critical
Publication of DE69837170D1 publication Critical patent/DE69837170D1/de
Publication of DE69837170T2 publication Critical patent/DE69837170T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C07K1/08—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using activating agents
    • C07K1/086—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using activating agents containing sulfur
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
    • C07K1/023—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution using racemisation inhibiting agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
    • C07K1/026—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution by fragment condensation in solution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
DE69837170T 1997-06-13 1998-06-12 Festphasige native chemische Ligation von ungeschützten oder n-cystein-geschützten Peptiden in wässrigen Lösungen Expired - Fee Related DE69837170T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4955397P 1997-06-13 1997-06-13
US49553P 1997-06-13

Publications (2)

Publication Number Publication Date
DE69837170D1 DE69837170D1 (de) 2007-04-05
DE69837170T2 true DE69837170T2 (de) 2007-11-22

Family

ID=21960431

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69837170T Expired - Fee Related DE69837170T2 (de) 1997-06-13 1998-06-12 Festphasige native chemische Ligation von ungeschützten oder n-cystein-geschützten Peptiden in wässrigen Lösungen
DE69828287T Expired - Fee Related DE69828287T2 (de) 1997-06-13 1998-06-12 Festphasige native chemische ligation von ungeschützten oder n-cystein-geschützten peptiden in wässrigen lösungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69828287T Expired - Fee Related DE69828287T2 (de) 1997-06-13 1998-06-12 Festphasige native chemische ligation von ungeschützten oder n-cystein-geschützten peptiden in wässrigen lösungen

Country Status (9)

Country Link
US (4) US6326468B1 (cg-RX-API-DMAC10.html)
EP (1) EP1001968B1 (cg-RX-API-DMAC10.html)
JP (1) JP2002505672A (cg-RX-API-DMAC10.html)
AT (2) ATE354584T1 (cg-RX-API-DMAC10.html)
AU (1) AU745094B2 (cg-RX-API-DMAC10.html)
CA (1) CA2292724A1 (cg-RX-API-DMAC10.html)
DE (2) DE69837170T2 (cg-RX-API-DMAC10.html)
ES (2) ES2235336T3 (cg-RX-API-DMAC10.html)
WO (1) WO1998056807A1 (cg-RX-API-DMAC10.html)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184344B1 (en) * 1995-05-04 2001-02-06 The Scripps Research Institute Synthesis of proteins by native chemical ligation
US6849428B1 (en) * 1997-03-05 2005-02-01 New England Biolabs, Inc. Intein-mediated protein ligation of expressed proteins
DE69837170T2 (de) * 1997-06-13 2007-11-22 Amylin Pharmaceuticals, Inc., San Diego Festphasige native chemische Ligation von ungeschützten oder n-cystein-geschützten Peptiden in wässrigen Lösungen
US6844161B2 (en) 1997-09-04 2005-01-18 Gryphon Therapeutics, Inc. Modular protein libraries and methods of preparation
AUPP589598A0 (en) 1998-09-14 1998-10-08 University Of Queensland, The Novel peptides
US7001745B1 (en) * 1998-09-30 2006-02-21 New England Biolabs, Inc. Intein mediated peptide ligation
EP1159289A1 (en) * 1999-03-11 2001-12-05 Gryphon Sciences Chemical synthesis and use of soluble membrane protein receptor domains
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
EP1307214A4 (en) * 2000-08-11 2006-01-18 Invitrogen Corp HIGHLY HOMOGENEOUS MOLECULAR MARKERS FOR ECTROPHORESIS
US20040014082A1 (en) * 2000-08-11 2004-01-22 Invitrogen Corporation Highly homogeneous molecular markers for electrophoresis
US6977292B2 (en) * 2000-09-01 2005-12-20 Gryphon Therapeutics Nucleophile-stable thioester generating compounds, methods of production and use
US7273923B2 (en) * 2001-01-22 2007-09-25 Sangamo Biosciences, Inc. Zinc finger proteins for DNA binding and gene regulation in plants
ATE346950T1 (de) * 2001-03-09 2006-12-15 Boston Probes Inc Kombinationsoligomere betreffende verfahren, kits und zusammensetzungen
GB0113657D0 (en) * 2001-06-05 2001-07-25 Geneprot Inc Improved native chemical ligation with three or more components
EP2292273A3 (en) 2001-10-10 2011-11-23 BioGeneriX AG Remodeling and glycoconjugation of peptides
WO2003106615A2 (en) * 2002-06-10 2003-12-24 Geneprot, Inc. Post-cleavage sulfur deprotection for convergent protein synthesis by chemical ligation
ATE312605T1 (de) * 2002-06-29 2005-12-15 Aquanova Ger Solubilisate Tech Isoflavonkonzentrate sowie verfahren zu ihrer herstellung
US7166574B2 (en) * 2002-08-20 2007-01-23 Biosurface Engineering Technologies, Inc. Synthetic heparin-binding growth factor analogs
US7598224B2 (en) 2002-08-20 2009-10-06 Biosurface Engineering Technologies, Inc. Dual chain synthetic heparin-binding growth factor analogs
US8227411B2 (en) 2002-08-20 2012-07-24 BioSurface Engineering Technologies, Incle FGF growth factor analogs
WO2004053460A2 (en) * 2002-12-11 2004-06-24 New England Biolabs, Inc. Carrier-ligand fusions and uses thereof
US8034900B2 (en) * 2002-12-30 2011-10-11 Amylin Pharmaceuticals, Inc. Water-soluble thioester and selenoester compounds and methods for making and using the same
CA2522345A1 (en) 2003-04-09 2004-11-18 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
SI1624891T2 (sl) * 2003-05-06 2013-09-30 Biogen Idec Hemophilia Inc. Strjevalni faktor-FC himerni proteini za zdravljenje hemofilije
WO2004105685A2 (en) * 2003-05-22 2004-12-09 Gryphon Therapeutics, Inc. Displaceable linker solid phase chemical ligation
US7414028B1 (en) 2004-02-04 2008-08-19 Biosurface Engineering Technologies, Inc. Growth factor analogs
US20080227696A1 (en) 2005-02-22 2008-09-18 Biosurface Engineering Technologies, Inc. Single branch heparin-binding growth factor analogs
US20060024347A1 (en) * 2004-02-10 2006-02-02 Biosurface Engineering Technologies, Inc. Bioactive peptide coatings
US7671012B2 (en) 2004-02-10 2010-03-02 Biosurface Engineering Technologies, Inc. Formulations and methods for delivery of growth factor analogs
US7528105B1 (en) 2004-02-10 2009-05-05 Biosurface Engineering Technologies Heterodimeric chain synthetic heparin-binding growth factor analogs
JP4895826B2 (ja) 2004-02-20 2012-03-14 バイオサーフェス エンジニアリング テクノロジーズ,インク. 骨形成蛋白−2の正のモジュレーター
US7910593B2 (en) 2004-04-09 2011-03-22 Chugai Seiyaku Kabushiki Kaisha Water-soluble prodrugs
EP1749022A2 (en) * 2004-05-24 2007-02-07 Rigel Pharmaceuticals, Inc. Methods for cyclizing synthetic polymers
KR20080003849A (ko) 2005-03-31 2008-01-08 아밀린 파마슈티칼스, 인크. 비만 및 섭식 장애의 조절, 예방 및 치료를 위한 조성물 및방법
TW200744603A (en) 2005-08-22 2007-12-16 Chugai Pharmaceutical Co Ltd Novel anticancer concomitant drug
US7674881B2 (en) * 2005-10-07 2010-03-09 The University Of Chicago Convergent synthesis of proteins by kinetically controlled ligation
US20090118271A1 (en) * 2005-10-19 2009-05-07 Chugai Seiyaku Kabushiki Kaisha Preventive or Therapeutic Agents for Pancreatic Cancer, Ovarian Cancer, or Liver Cancer Comprising a Novel Water-Soluble Prodrug
US7820172B1 (en) 2006-06-01 2010-10-26 Biosurface Engineering Technologies, Inc. Laminin-derived multi-domain peptides
CA2692240C (en) 2006-06-22 2018-03-13 Biosurface Engineering Technologies, Inc. Composition and method for delivery of bmp-2 amplifier/co-activator for enhancement of osteogenesis
EP2120985B1 (en) 2007-02-05 2012-06-27 Amylin Pharmaceuticals, Inc. FN-38 peptides for use in the treatment of psychotic and anxiety disorders
WO2009032133A2 (en) * 2007-08-28 2009-03-12 Ipsen Pharma S.A.S. Methods and intermediates for chemical synthesis of polypeptides and proteins
EP2536287A4 (en) * 2010-02-18 2015-10-07 Advanced Proteome Therapeutics Inc SPECIFIC SITE SIZE OF PROTEINS USING CHEMICAL MODIFICATION TO PROMOTE PROTEIN CONJUGATE FORMATION, PROTEIN DIMER FORMATION, AND AGRAFTED PEPTIDES
MX349054B (es) 2010-09-28 2017-07-07 Aegerion Pharmaceuticals Inc Leptinas altamente solubles.
BR112013007442A2 (pt) 2010-09-28 2019-09-24 Amylin Pharmaceuticals Llc polipeptídeos construídos tendo duração de ação realçada
DK2729160T3 (da) 2011-07-08 2019-07-01 Aegerion Pharmaceuticals Inc Manipulerede polypeptider, der har forbedret virkningstid og reduceret immunogenicitet
JP6006309B2 (ja) 2011-07-08 2016-10-12 アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド
FR2981352B1 (fr) * 2011-10-17 2015-07-03 Centre Nat Rech Scient Procede de synthese de proteines
US9545449B2 (en) 2012-05-11 2017-01-17 Advanced Proteone Therapeutics Inc. Site-specific labeling and targeted delivery of proteins for the treatment of cancer
WO2013177231A1 (en) 2012-05-21 2013-11-28 Massachusetts Institute Of Technology Translocation of non-natural chemical entities through anthrax protective antigen pore
SG11201505926VA (en) 2013-03-15 2015-09-29 Biogen Ma Inc Factor ix polypeptide formulations
US11273176B2 (en) 2016-03-02 2022-03-15 The Brigham And Women's Hospital, Inc. Use of PLA2G5-deficient suppressive macrophages in suppression of inflammation
EP3590951A4 (en) * 2017-03-02 2021-01-06 Glytech, Inc. PROCESS FOR PRODUCING AN AMINO ACID POLYMER
KR20210072021A (ko) 2018-10-01 2021-06-16 유니베르시떼 드 제네브 생물학 분석에 적합한 복수의 폴리펩티드 변이체의 생산 방법
KR102769851B1 (ko) * 2018-11-30 2025-02-20 가부시키가이샤 도우사 고가쿠 겐큐쇼 펩티드 티오에스테르 및 펩티드의 신규 제조 방법
AU2020361681A1 (en) 2019-10-10 2022-05-05 1859, Inc. Methods and systems for microfluidic screening
US20210230218A1 (en) * 2019-10-23 2021-07-29 Mabplex International, Ltd. Oligopeptide linker intermediate and preparation method thereof
WO2022266467A2 (en) 2021-06-17 2022-12-22 Dana-Farber Cancer Institute, Inc. Recombinant histone polypeptide and uses thereof
WO2024146707A1 (en) 2023-01-06 2024-07-11 Université De Genève Variant ligand conjugates for payload delivery

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5064940A (en) * 1988-05-11 1991-11-12 Protein Technologies, Inc. Premixed dry reagent containing a protected amino acid and an activating agent for use in solid phase protein synthesis
US5101059A (en) * 1989-12-05 1992-03-31 Research Corporation Technologies, Inc. Amino acid protecting groups
DK0832096T3 (da) * 1995-05-04 2001-10-01 Scripps Research Inst Syntese af proteiner ved nativ kemisk ligering
JP4358307B2 (ja) * 1996-12-24 2009-11-04 ザ スクリップス リサーチ インスティテュート 一般的化学結合
DE69837170T2 (de) * 1997-06-13 2007-11-22 Amylin Pharmaceuticals, Inc., San Diego Festphasige native chemische Ligation von ungeschützten oder n-cystein-geschützten Peptiden in wässrigen Lösungen
US6329468B1 (en) * 2000-01-21 2001-12-11 Bostik Findley, Inc. Hot melt adhesive based on semicrystalline flexible polyolefins

Also Published As

Publication number Publication date
DE69837170D1 (de) 2007-04-05
ATE285415T1 (de) 2005-01-15
AU8069598A (en) 1998-12-30
ES2235336T3 (es) 2005-07-01
WO1998056807A1 (en) 1998-12-17
US20020132975A1 (en) 2002-09-19
US7094871B2 (en) 2006-08-22
ATE354584T1 (de) 2007-03-15
AU745094B2 (en) 2002-03-14
US20050209440A1 (en) 2005-09-22
DE69828287D1 (de) 2005-01-27
CA2292724A1 (en) 1998-12-17
EP1001968A1 (en) 2000-05-24
US20020169282A1 (en) 2002-11-14
JP2002505672A (ja) 2002-02-19
ES2282788T3 (es) 2007-10-16
EP1001968B1 (en) 2004-12-22
US6326468B1 (en) 2001-12-04
DE69828287T2 (de) 2005-12-15
US7030217B2 (en) 2006-04-18

Similar Documents

Publication Publication Date Title
DE69828287T2 (de) Festphasige native chemische ligation von ungeschützten oder n-cystein-geschützten peptiden in wässrigen lösungen
EP0285562B1 (de) Kunstharz
DE69430312T2 (de) Peralkylierte oligopeptidmischungen
DE68916722T2 (de) Urethan geschützte aminosäuren-n-carboxyanhydride.
DE3788910T2 (de) Methode für die Synthese eines Peptides, das eine nicht peptidartige Bindung enthält.
DE60208684T2 (de) Verbesserte native chemische ligation mit drei oder mehreren komponenten
JPS6140680B2 (cg-RX-API-DMAC10.html)
JP2002525376A (ja) アミド結合形成のための補助基
DE69325987T2 (de) Verfahren zur Herstellung von Lachs-Calcitonin
DE69021079T2 (de) Verfahren und reagens zur herstellung der aminosäure thiohydantoin.
DE69604759T2 (de) N alpha-2-(4-nitrophenylsulfonyl)ethoxycarbonyl-aminosäuren
EP0051205A1 (de) Neues Tridekapeptid, Verfahren zu seiner Herstellung und Verwendung
EP0589927A1 (de) Geschützter aminosäurebaustein, herstellung und verwendung
DE69708420T2 (de) Herstellung von gereinigten (Poly)Peptiden
JP2002531529A (ja) 検出可能なリポーター部分を有する生物学的に活性な接合体、及びその同定方法
DE60303314T2 (de) Verfahren zum carboxygruppenschutz der säuren c-terminalen aminosäuren bei chemischer verknüpfung von oligopeptiden
EP1518862B1 (en) Solid phase native chemical ligation of unprotected or n-terminal cysteine protected peptides in aqueous solution
DE2505712A1 (de) Traegergebundene sowie biologisch aktive peptide und herstellungsverfahren dafuer
DE10154744A1 (de) Isotopencodierte Affinitätsmarker
DE68912090T2 (de) Calcitonin-Derivate und deren Salze.
DE2703121A1 (de) Synthetische pentapeptide und sie enthaltende arzneimittel
RU2828026C2 (ru) Способ получения пептидов, или белков, или пептидомиметиков
DE3931731C2 (de) Verfahren zur Festphasenpeptidsynthese
DE2649848A1 (de) Traegergebundene peptide, pth-peptidzwischenprodukte sowie ihre herstellung
Samarasimhareddy et al. Epimerization free synthesis of O-acyl isodipeptides employing COMU

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: AMYLIN PHARMACEUTICALS, INC., SAN DIEGO, CALIF, US

8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee